|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TBL1X |
Gene summary for TBL1X |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TBL1X | Gene ID | 6907 |
| Gene name | transducin beta like 1 X-linked | |
| Gene Alias | CHNG8 | |
| Cytomap | Xp22.31-p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A024RBV9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6907 | TBL1X | CCI_2 | Human | Cervix | CC | 4.25e-04 | 6.25e-01 | 0.5249 |
| 6907 | TBL1X | P2T-E | Human | Esophagus | ESCC | 1.71e-06 | 2.01e-01 | 0.1177 |
| 6907 | TBL1X | P4T-E | Human | Esophagus | ESCC | 3.54e-06 | 2.27e-01 | 0.1323 |
| 6907 | TBL1X | P5T-E | Human | Esophagus | ESCC | 4.50e-04 | 1.20e-01 | 0.1327 |
| 6907 | TBL1X | P8T-E | Human | Esophagus | ESCC | 3.39e-07 | 1.55e-01 | 0.0889 |
| 6907 | TBL1X | P9T-E | Human | Esophagus | ESCC | 4.08e-06 | 1.50e-01 | 0.1131 |
| 6907 | TBL1X | P10T-E | Human | Esophagus | ESCC | 2.04e-06 | 7.28e-02 | 0.116 |
| 6907 | TBL1X | P12T-E | Human | Esophagus | ESCC | 8.67e-23 | 3.98e-01 | 0.1122 |
| 6907 | TBL1X | P15T-E | Human | Esophagus | ESCC | 2.11e-09 | 2.43e-01 | 0.1149 |
| 6907 | TBL1X | P16T-E | Human | Esophagus | ESCC | 6.11e-14 | 1.47e-01 | 0.1153 |
| 6907 | TBL1X | P20T-E | Human | Esophagus | ESCC | 3.32e-02 | 5.59e-02 | 0.1124 |
| 6907 | TBL1X | P21T-E | Human | Esophagus | ESCC | 8.34e-04 | 9.17e-02 | 0.1617 |
| 6907 | TBL1X | P23T-E | Human | Esophagus | ESCC | 9.80e-11 | 3.79e-01 | 0.108 |
| 6907 | TBL1X | P26T-E | Human | Esophagus | ESCC | 4.15e-27 | 5.64e-01 | 0.1276 |
| 6907 | TBL1X | P27T-E | Human | Esophagus | ESCC | 1.25e-09 | 1.54e-01 | 0.1055 |
| 6907 | TBL1X | P28T-E | Human | Esophagus | ESCC | 1.54e-16 | 3.22e-01 | 0.1149 |
| 6907 | TBL1X | P30T-E | Human | Esophagus | ESCC | 1.87e-22 | 7.93e-01 | 0.137 |
| 6907 | TBL1X | P31T-E | Human | Esophagus | ESCC | 4.04e-02 | 3.27e-02 | 0.1251 |
| 6907 | TBL1X | P36T-E | Human | Esophagus | ESCC | 3.96e-03 | 2.22e-01 | 0.1187 |
| 6907 | TBL1X | P39T-E | Human | Esophagus | ESCC | 5.71e-12 | 2.54e-01 | 0.0894 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:019873820 | Thyroid | HT | cell-cell signaling by wnt | 48/1272 | 446/18723 | 1.07e-03 | 1.07e-02 | 48 |
| GO:006007019 | Thyroid | HT | canonical Wnt signaling pathway | 34/1272 | 303/18723 | 2.76e-03 | 2.27e-02 | 34 |
| GO:006082820 | Thyroid | HT | regulation of canonical Wnt signaling pathway | 29/1272 | 253/18723 | 4.01e-03 | 2.96e-02 | 29 |
| GO:003011120 | Thyroid | HT | regulation of Wnt signaling pathway | 35/1272 | 328/18723 | 5.41e-03 | 3.58e-02 | 35 |
| GO:0010498113 | Thyroid | PTC | proteasomal protein catabolic process | 297/5968 | 490/18723 | 4.58e-40 | 9.63e-37 | 297 |
| GO:0043161113 | Thyroid | PTC | proteasome-mediated ubiquitin-dependent protein catabolic process | 254/5968 | 412/18723 | 3.91e-36 | 4.54e-33 | 254 |
| GO:0031647113 | Thyroid | PTC | regulation of protein stability | 174/5968 | 298/18723 | 2.05e-21 | 4.05e-19 | 174 |
| GO:001657010 | Thyroid | PTC | histone modification | 235/5968 | 463/18723 | 1.17e-17 | 1.15e-15 | 235 |
| GO:0050821113 | Thyroid | PTC | protein stabilization | 115/5968 | 191/18723 | 5.67e-16 | 4.31e-14 | 115 |
| GO:0016055110 | Thyroid | PTC | Wnt signaling pathway | 217/5968 | 444/18723 | 3.71e-14 | 2.30e-12 | 217 |
| GO:0198738110 | Thyroid | PTC | cell-cell signaling by wnt | 217/5968 | 446/18723 | 6.68e-14 | 3.73e-12 | 217 |
| GO:0030111110 | Thyroid | PTC | regulation of Wnt signaling pathway | 163/5968 | 328/18723 | 1.05e-11 | 4.29e-10 | 163 |
| GO:0060828110 | Thyroid | PTC | regulation of canonical Wnt signaling pathway | 123/5968 | 253/18723 | 1.83e-08 | 4.26e-07 | 123 |
| GO:0060070110 | Thyroid | PTC | canonical Wnt signaling pathway | 141/5968 | 303/18723 | 5.71e-08 | 1.21e-06 | 141 |
| GO:003017719 | Thyroid | PTC | positive regulation of Wnt signaling pathway | 72/5968 | 140/18723 | 1.16e-06 | 1.69e-05 | 72 |
| GO:00356017 | Thyroid | PTC | protein deacylation | 58/5968 | 112/18723 | 9.29e-06 | 1.05e-04 | 58 |
| GO:00165756 | Thyroid | PTC | histone deacetylation | 45/5968 | 82/18723 | 1.34e-05 | 1.45e-04 | 45 |
| GO:00064767 | Thyroid | PTC | protein deacetylation | 53/5968 | 101/18723 | 1.36e-05 | 1.47e-04 | 53 |
| GO:009026319 | Thyroid | PTC | positive regulation of canonical Wnt signaling pathway | 55/5968 | 106/18723 | 1.45e-05 | 1.55e-04 | 55 |
| GO:00987327 | Thyroid | PTC | macromolecule deacylation | 58/5968 | 116/18723 | 3.59e-05 | 3.36e-04 | 58 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa0431012 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa043108 | Lung | IAC | Wnt signaling pathway | 40/1053 | 171/8465 | 4.56e-05 | 7.06e-04 | 4.69e-04 | 40 |
| hsa0431011 | Lung | IAC | Wnt signaling pathway | 40/1053 | 171/8465 | 4.56e-05 | 7.06e-04 | 4.69e-04 | 40 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TBL1X | SNV | Missense_Mutation | c.1673N>T | p.Gly558Val | p.G558V | O60907 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| TBL1X | SNV | Missense_Mutation | c.947N>T | p.Thr316Met | p.T316M | O60907 | protein_coding | deleterious(0.04) | benign(0.103) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD | |
| TBL1X | SNV | Missense_Mutation | c.625N>A | p.Ala209Thr | p.A209T | O60907 | protein_coding | tolerated(0.61) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TBL1X | SNV | Missense_Mutation | c.1011N>T | p.Trp337Cys | p.W337C | O60907 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TBL1X | SNV | Missense_Mutation | c.1459N>C | p.Val487Leu | p.V487L | O60907 | protein_coding | deleterious(0.01) | possibly_damaging(0.9) | TCGA-E2-A1IL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TBL1X | insertion | In_Frame_Ins | novel | c.869_870insAAAATGTTTCTGGAAACAAAAGAGCCCTTTAAGTGTGTTTCT | p.Asp290delinsGluLysCysPheTrpLysGlnLysSerProLeuSerValPheLeu | p.D290delinsEKCFWKQKSPLSVFL | O60907 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| TBL1X | SNV | Missense_Mutation | c.1140N>C | p.Gln380His | p.Q380H | O60907 | protein_coding | deleterious(0.05) | probably_damaging(0.967) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| TBL1X | SNV | Missense_Mutation | rs746301021 | c.1726N>T | p.Arg576Trp | p.R576W | O60907 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AA-3695-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TBL1X | SNV | Missense_Mutation | rs752103477 | c.1499N>T | p.Thr500Met | p.T500M | O60907 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TBL1X | SNV | Missense_Mutation | c.625N>A | p.Ala209Thr | p.A209T | O60907 | protein_coding | tolerated(0.61) | benign(0) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |